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Restoration of Suppressed Baroreflex Sensitivity in
Rats with Hereditary Diabetes Insipidus (Brattleboro
Rats) by Arginine-Vasopressin and DDAVP
Yutaka Imai, Peter L. Nolan, and Colin I. Johnston
From the Monash University Department of Medicine, Prince Henry's Hospital, St. Kilda Road, Melbourne, Victoria, Australia
SUMMARY. To determine the influence of vasopressin on baroreceptor reflex mechanisms,
baroreflex function in Brattleboro rats was compared with that in normal Long-Evans rats.
Baroreflex function was assessed in conscious unrestrained rats during increases in blood pressure
with phenylephrine (200 Mg/kg per min for 10 seconds). The baroreflex function line was obtained
by plotting the log (pulse period) against the preceding systolic pressure on a beat-by-beat basis.
The slope of the baroreflex function line (baroreflex function slope) in Long-Evans rats [(19.0 ±
1.4) X 10"4, mean ± SEM, n = 34] was significantly steeper than that in Brattleboro rats [(6.9 ±
0.6) X 10~\ n = 44, P < 0.001]. A subpressor intravenous infusion of arginine8-vasopressin (2
ng/kg per min for 2 hours), which elevated plasma vasopressin to 48.1 ± 6.8 pg/ml, caused
bradycardia and increased the baroreflex function slope in Brattleboro rats, from (7.5 ± 1.0) x
10"" to within the normal Long-Evans range [(17.0 ± 0.8) x 10~\ n = 7, P < 0.001]. The basal
pulse period and the baroreflex function slope in Brattleboro rats [(7.0 ± 0.9) x 10~4] was also
increased significantly to (12.0 ± 1.7) X 10"* (n = 11, P < 0.01) by an infusion of l-desamino-8-
D-arginine vasopressin, (2 ng/kg per min for 2 hours), a vasopressin analogue with potent
antidiuretic but minimal vascular actions. Acute volume expansion, which increased body weight
significantly, did not change the baroreflex function slope in Brattleboro rats [(7.7 ± 1.1) X 10"4
vs. (8.2 ± 1.7) X 10~\ n = 6]. A specific vasopressin vascular receptor antagonist [d(CH2)5
Tyr(Me)AVP], although blocking the pressor effect of exogenous vasopressin, did not change the
pulse period or the baroreflex function slope [(16.0 ± 2.3) X 10~* vs. (19.0 ± 1.7) X 10"*, n = 6)]
in normal Long-Evans rats. The results obtained in Brattleboro rats and the change in baroreflex
sensitivity brought about by infusions of vasopressin and DDAVP provide strong evidence that
vasopressin may be an important physiological modulator of baroreflex function. (Circ Res 53:
140-149, 1983)
SEVERAL recent findings indicate that the vasocon-
strictor property of vasopressin may have physio-
logical significance. Although low infusion rates of
vasopressin which produce plasma levels that are
close to the physiological range can elevate blood
pressure (Szczepanska-Sadowska, 1973; Pullan et
al., 1980), circulatory reflex mechanisms normally
buffer the arterial pressure increase following vaso-
pressin vasoconstriction (Johnston et al., 1981). The
pressor response to vasopressin is remarkably poten-
tiated when reflex buffering mechanisms are elimi-
nated by sinoaortic denervation (Cowley et al., 1974)
or pharmacological blockade of the sympathetic
nervous system (Pullan et al., 1980). Furthermore,
Cowley et al. (1974) and Matsuguchi and Schmid
(1982) have demonstrated that after elimination of
baroreflex buffering, the pressor response to vaso-
pressin was augmented more than those to pheny-
lepehrine or norepinephrine. It was also reported
recently that even small elevations in plasma vaso-
pressin caused considerable bradycardia without
change in arterial pressure (Pullan et al., 1980;
Mohring et al., 1981). Mohring et al. (1981) also
demonstrated that heart rate fell more for a given
increase in arterial pressure during infusion of va-
sopressin than during an infusion of phenylephrine
or norepinephrine. These results imply that vaso-
pressin specifically modulates the baroreflex path-
way. Whether these are peripherally or centrally
mediated effects of vasopressin is not known. Recent
studies suggest that vasopressin and/or central va-
sopressinergic neurones can alter the function of the
baroreflex or that of central cardiovascular control
systems. Centrally administered vasopressin causes
hypertension and tachycardia in rats (Matsuguchi et
al., 1982; Pittman et al., 1982; Imai et al., 1983)
Several recent reports also showed that centrally
administered vasopressin increased the baroreflex
sensitivity in rats (Izdebska et al., 1982; Imai et al.,
1983). On the other hand, Brattstrom and Kalkoff
(1970) reported, to the contrary, that intracisternal
administration of vasopressin attenuated the blood
pressure lowering effect of carotid sinus stimulation
in dogs, suggesting suppressed inhibition of central
sympathetic vasomotor activity. Extra-hypotha-
lamic-pituitary vasopressinergjc neurones project to
some regions of the central vasomotor centers (Saper
et al., 1976; Buijs et al., 1978; Sofroniew, 1980).
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Berecek et al. (1982) reported that stimulation of the
paraventricular nucleus, a vasopressin synthetizing
nucleus, produced frequency dependent bradycar-
dia and hypotension in rats. However, it was also
reported that stimulation of vasopressin synthetizing
nuclei attenuates the bradycardia produced by ca-
rotid sinus stimulation in cats (Ciriello and Calaresu,
1980). Intra-cisternal administration of vasopressin
also attenuated the blood pressure-lowering effect
of carotid sinus stimulation in dogs (Brattstrdm and
Kalkoff, 1970). Thus, under normal conditions, en-
dogenous vasopressin may have circulatory effects
both by direct vasoconstriction and by a baroreflex
mechanism. In the present study, the role of endog-
enous vasopressin in influencing the baroreceptor
reflex mechanism has been examined by comparing
baroreflex function in Brattleboro rats with heredi-
tary hypothalamic diabetes insipidus with that in
Long-Evans rats of the parent strain. The mecha-
nism of action of vasopressin on baroreflex function
also was studied.
Methods
Male homozygous Brattleboro rats with hereditary hy-
pothalamic diabetes insipidus (DI rats) and male Long-
Evans rats of the parent strain (LE rats) weighing 200-400
g and aged 24-27 weeks were used. All rats were allowed
free access to chow and water until the surgical procedure.
Under ether anaesthesia, the left femoral artery and vein
were catheterized, using polyethylene tubing. The tip of
the arterial catheter (Inrramedic PE100; Clay Adams) was
tapered by heating for insertion into the femoral artery.
Inrramedic PE50 was used as a venous catheter. In some
rats, the right femoral vein was also catheterized for the
continuous infusion of drugs or 5% dextrose solution. The
catheters were passed subcutaneously and brought out on
the neck. Catheters were filled with heparinized saline
(1000 IU/ml) and sealed by heating. During surgery, 15
mg of aminobenzyl penicillin were administered topically
and intraperitoneally. Rats were allowed to recover for at
least 24 hours after surgery and were conscious and un-
restrained during subsequent studies.
During each experiment, rats were placed in rectangular
boxes (30 X 17 X 17 cm) without any restriction of
movement, and were allowed free access to water. Blood
pressure was recorded from the femoral arterial catheter
using a P23Db Statham pressure transducer. Pulse period
was monitored with a period meter (Baker Institute model
Unicon kfh 122B). Both parameters were recorded contin-
uously on a Brush recorder (model 440). One hour was
allowed for stabilization of the blood pressure and pulse
period before measurement of baroreflex function. The
arterial pressure dose-response curves for several vaso-
pressor substances were obtained.
The drugs used in the present study were: phenyleph-
rine hydrochloride (Sigma), (Arg8)-vasopressin (Calbi-
ochem), l-desamino-8-D-arginine vasopressin (DDAVP,
Minirin, Ferring AB), Pmp\ 0-methyl-TyT2-(Arg8)-vaso-
pressin [d(CH2)5Tyr(Me)AVP, Peninsula Laboratories], an-
giotensin II (Hypertensin, Ciba) and atropine sulfate
(David Bull Laboratories). Stock solutions of arginine-
vasopressin (AVP) and its analogues were prepared in 0.1
N acetic acid. Phenylephrine and angiotensin II were
dissolved in 0.9% saline. All drug solutions were diluted
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to the desired concentrations with 0.9% saline. The solu-
tion of phenylephrine was infused at rates up to 22 nl/
sec by an infusion pump (Harvard apparatus model 660-
910/920). Solutions of vasopressin or its analogues were
infused at a rate of 30 fil/min by an infusion pump
(DELTA model MHRE 22). Infusion of an equivalent
volume of vehicle was shown to have no significant
cardiohemodynamic effects. All drug solutions were in-
jected or infused through the implanted venous catheter.
Measurement of Baroreflex Function
Baroreflex function was assessed in conscious unre-
strained rats by pharmacological increases of blood pres-
sure with phenylephrine, according to the method of
Smyth et al. (1969). Phenylephrine was infused at a rate
of 200 Mg/kg per min for 10 seconds to obtain nearly
maximum pressor effect without marked irregularity in
pulse period. Pulse period (log scale) was plotted against
systolic blood pressure on a beat-by-beat basis to provide
the baroreflex function curve. Only those points that were
located on the linear portion of this curve were used to
calculate what we have termed the 'baroreflex function
line' (Fig. 1). The sensitivity of the reflex was determined
by the slope of baroreflex function line (baroreflex func-
tion slope). The slope was calculated from the plot of the
systolic blood pressure and log (pulse period) using regres-
sion analysis and expressed as follows:
Slope = A log PP/A SBP, where PP is pulse period (msec)
and SBP is systolic blood pressure (mm Hg).
6OH
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FIGURE 1. Pressor dose-response curves against phenylephrine in LE
and Dl rats.
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The sigmoid curve which depicts a complete baroreflex
function was not obtained in the present experiments.
Decreasing blood pressure with nitroprusside caused only
a very small decrease in pulse period in the conscious rat
(unpublished data); these points did not fall on the linear
portion of the baroreflex function line and were therefore
not included in the analysis.
Experimental Protocols
Experiments were performed as described below. Each
rat was studied twice with an interval of at least 48 hours
between successive experiments. The age, body weight,
control values of mean arterial pressure, pulse period, and
heart rate are shown in Table 1.
Experiment 1. Difference of Baroreflex Sensitivity between
LE and Dl Rats
Baroreflex function was determined in 34 LE and 44 DI
rats. As a preliminary experiment, the pressor-dose re-
sponse curve to phenylephrine at rates of 12.5, 25, and
50 Mg/kg per min for 1 minute was examined in 24 LE
rats and 23 DI rats. At least 10 minutes were allowed
between increasing doses of phenylephrine. The time to
attain the peak pressor response was calculated.
Experiment 2. Effect of Subpressor Dose of AVP on
Baroreflex Function in Dl Rats
To determine the subpressor dose of AVP, the pressor-
dose response relationship of AVP at rates of 30, 60, and
120 ng/kg per min for 1 minute was examined in 27 LE
rats and 15 DI rats. The subpressor dose of AVP was
determined by extrapolation of this dose-response curve.
The baroreflex function was examined in seven DI rats
before and during infusion of the subpressor dose of AVP.
After establishing a control baroreflex function line, AVP
was infused at a rate of 2 ng/kg per min for 2 hours, and
baroreflex function was reexamined during AVP infusion.
At the conclusion of this experiment, the rat was decapi-
tated and blood was collected for measurement of plasma
vasopressin.
Experiment 3. Effect of DDAVP on Baroreflex Function in Dl
Rats
The baroreflex function was examined in 11 DI rats
before and during infusion of DDAVP, a vasopressin
analogue with potent anridiuretic activities and with min-
imal cardiovascular effects. After control baroreflex func-
tion had been determined, DDAVP was infused at a rate
of 2 ng/kg per min for 2 hours, and baroreflex function
was reexamined during this period.
Experiment 4. Effect of Volume Expansion on Baroreflex
Function in DI Rats
The effect of acute volume expansion on baroreflex
function was examined in six DI rats. After control baro-
Circulation Research/Vol. 53, No. 2, August 1983
reflex function had been measured, an initial injection of
15 ml/kg of 5% dextrose solution was made, followed by
infusion of a 5% dextrose solution at 1 ml/kg per min for
2 hours. The baroreflex function was reexamined during
volume expansion. Body weight and arterial blood he-
matocrit were measured before infusion and just after the
second measurement of baroreflex function.
Experiment 5. Effect of a Specific Vasopressin Vascular
Receptor Antagonist on Baroreflex Function in LE Rats
The effect of the vasopressin specific vascular receptor
antagonist, d(CH2)5Tyr(Me)AVP (Kruszynski et al., 1980),
on cardiohemodynamics was examined in nine LE rats.
The baroreflex function was examined in six of these
animals before and during infusion of
d(CH2)5Tyr(Me)AVP. After testing the control baroreflex
function, d(CH2)5Tyr(Me)AVP was injected in a dose of 1
Mg/kg followed by infusion at 5 ^g/kg per hr for 2 hours.
Baroreflex function was reexamined during this period.
To establish that this dose of antagonist was effective in
these rats, the pressor effect of vasopressin in a dose of
100 ng/kg was examined before and during
d(CH2)5Tyr(Me)AVP treatment.
Experiment 6. Effect of Combined Treatment with AVP and
Specific Vasopressin Vascular Receptor Antagonist on
Baroreflex Function in DI Rats
The baroreflex function was examined in five DI rats
before and during combined treatment with AVP and
specific vasopressin vascular receptor antagonist. After
testing the control baroreflex function, AVP was infused
at a rate of 2 ng/kg per min for 2 hours, and baroreflex
function was reexamined during AVP infusion. There-
after, vasopressin vascular receptor antagonist,
d(CH2)5TyT(Me)AVP, was administered in addition to
AVP. The dose and procedure of administration of antag-
onist is the same as that stated previously. The baroreflex
function was reexamined during combined treatment with
AVP and antagonist.
Experiment 7. Effect of Atropine on Baroreflex Sensitivity in
LE and Dl Rats
To determine the parasympathetic contribution to the
baroreflex in rats, the effect of atropine was examined in
six LE and six DI rats. After testing the control baroreflex
function, we injected 1 mg/kg of atropine sulphate, intra-
venously, and 15 minutes later, again examined baroreflex
function.
Analytical Methods
Plasma vasopressin concentration was measured in six
DI rats with and without infusion of AVP at a rate of 2
ng/kg per min for 2 hours. Plasma vasopressin concentra-
tion was determined by radioimmunoassay (Woods and
Johnston, 1982).
TABLE 1
Age, Body Weight, and Basal Values of Mean Arterial Pressure, Pulse Period, and Heart Rate in
LE and DI Rats
Rat
LE
DI
n
34
44
Age
(wks)
23.8 ± 1.2
26.5 ± 1.2
Body wt
(8)
327 ± 8
313 ± 6
MAP
(mm Hg)
96 ± 2
100 ± 4
Pulse
period
(msec)
150 ± 3
164 ±4f
Heart
Rate
(beats/min)
407 ± 9
375 ± 4*
* Significant difference from LE rat (P < 0.01); f P < 0.001.
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Antibodies to synthetic arginine-vasopressin were
raised in New Zealand White rabbits after conjugating the
peptide to bovine serum albumin by glutaraldehyde. The
dilution of antiserum that bound 50% of the tracer was a
final dilution of 1:120,000. The antibody cross-reacted
10% with synthetic lysine-vasopressin, 100% with
DDAVP, and less than 0.001% with synthetic oxytocin,
arginine vasotocin, and human neurophysins I and II.
Synthetic AVP (Ferring, A.B., Malmo, Sweden) was used
as standard. The rats were decapitated and blood was
collected into chilled heparinized tubes and, after centrif-
ugation, the plasma was separated, stored at —20°C, and
extracted with acetone/petroleum ether. The mean recov-
ery of AVP was 83.2 ± 2.8%, and was linear over the
range of 0-20 pg. The assay sensitivity was 0.6 pg/ml and
the intra- and interassay variability were 8.4% and 11.6%,
respectively.
Statistical Methods
All values reported are the mean ± SEM unless otherwise
stated. The dose-response curves for phenylephrine in LE
and DI rats were compared, using analysis of variance,
linear regression equations were calculated by the method
of least squares. The slopes of the regression line for
baroreflex function within a group were compared by
Student's t-test for paired comparison, and those between
groups were analyzed by one-way analysis of variance.
Results
Age, Body Weight, and Basal Values of Blood
Pressure and Pulse Period in LE and DI rats
As shown in Table 1, the body weight of DI rats
was slightly lower than that of LE rats, although the
DI rats were older. However, these differences were
not statistically significant. Although there was no
significant difference in basal mean arterial pressure
between LE and DI rats, the basal pulse period in
DI rats was significantly longer (P < 0.001) than
that in LE rats. Hence, conscious unrestrained DI
rats had a slower heart rate than LE rats.
Experiment 1. Baroreflex Sensitivity in LE and
DI Rats
There was no difference between the pressor
dose-response curves to phenylephrine in LE and
DI rats (Fig. 1). The time to attain peak mean arterial
pressure in response to 50 Mg/kg per min of phen-
ylephrine in DI rats (26.2 ± 2.3 seconds) was also
not significantly different from that in LE rats (26.1
±1.7 seconds).
Figure 2 illustrates a typical plot obtained after
phenylephrine infusion in a LE and DI rat over a
blood pressure range of 100-200 mm Hg. Figure 3
(left) compares the basal mean arterial pressure and
pulse period and average calculated baroreflex func-
tion line for LE and DI rats. All baroreflex function
slopes from LE and DI rats were plotted and together
with the mean ± 1 SD of the slopes, are illustrated
in Figure 3 (right). The baroreflex function slope in
LE rats [(19.0 ± 1.4) X 10~4] was significantly steeper
than that in DI rats [(6.9 ± 0.6) X 10~4, F,,76 = 73.5,
P < 0.001]. The baroreflex sensitivity in LE rats was
higher than that in DI rats, and hence the baroreflex
143
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FIGURE 2. Relationship between systolic blood pressure (SBP) and
pulse period obtained following phenylephrine infusion in a LE (open
circle) and DI (closed circle) rat. Vertical axis is plotted as log scale.
sensitivity is suppressed in Brattleboro rats which
lack vasopressin. Thus, for any given rise in blood
pressure, less bradycardia was seen in DI than LE
rats. The correlation coefficient between the changes
in pulse period and systolic blood pressure in LE
rats (0.91 ±0.01) was significantly greater than that
in DI rats (0.70 ± 0.04, P < 0.001), implying greater
variability in pulse period in the absence of AVP.
Experiment 2. Effect of a Subpressor Dose of
Vasopressin on Baroreflex Function in DI Rats
Arginine-vasopressin at a rate of 2 ng/kg per min
for 2 hours did not significantly change the mean
arterial pressure (98 ± 3 vs. 102 ± 2 mm Hg).
However, it did significantly prolong the pulse pe-
riod (165 ± 9 vs. 183 ± 11 msec, P < 0.01). DI rats
had no measurable vasopressin in their plasma. The
AVP infusion, 2 ng/kg per min, produced a plasma
AVP level of 48.1 ± 6.8 pg/ml after 2 hours in DI
rats. Figure 4 (left) shows the average calculated
baroreflex function lines before and during vaso-
pressin infusion. The regression line was shifted
upward during AVP infusion. The individual baro-
reflex function slopes obtained from each experi-
ment are shown in Figure 4 (right). The baroreflex
function slope during AVP infusion [(17.0 ± 0.8) X
10~4] was significantly steeper than that before AVP
infusion [(7.5 ± 1.0) X 10~4, P < 0.001] and not
different to that obtained in normal LE rats [(19.0 ±
1.4) X 10"4, F,,39 = 0.24, P > 0.05]. During AVP
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FIGURE 3. Baroreflex sensitivity in LE and Dl rats. The average calculated baroreflex function lines from L£ rats (open circle and solid line) and
from Dl rats (closed circle and dotted line) are shown in left figure. The symbols in left figure (open and closed circles) are the mean ± SEM of
pulse period (PP) and systolic blood pressure (SBP), respectively, at basal condition of the experiment. The vertical axis is plotted as log scale. All
points and the mean ± 7 so of all the baroreflex function slopes (baroreflex sensitivity) from LE rats (open circle) and Dl rats (closed circle) are
illustrated in right figure. A SBP: change m systolic blood pressure.
infusion all baroreflex function slopes fell within the
range of mean ± 1SD of the slopes found in LE rats
(Fig. 4, right).
Experiment 3. Effect of DDAVP on Baroreflex
Function in Dl Rats
Although DDAVP at a rate of 2 ng/kg per min
for 2 hours did not change the mean arterial pressure
in Dl rats (102 ± 3 vs. 101 ± 3 mm Hg), this dose
of DDAVP significantly increased the pulse period
from 157 ± 7 to 176 ± 6 msec (P < 0.01). This short
infusion of DDAVP did not change body weight
(300 ± 11 g before and 301 ± 10 g after).
Figure 5 (left) shows the average calculated baro-
reflex function lines before and during DDAVP in-
fusion. The regression line was shifted upward dur-
ing DDAVP infusion. The individual baroreflex
function slopes obtained from each experiment are
200-
Q
o
i
ISO-
IOO
— • — Dl »AT+ AVP
y2-02+l7-0«IO-«j
y>2ll+7S«IO'*I
-30 >-~
t
"20
z
C Q.
UJ
-10 go
BO 200
SBP (mmHg)
CONTROL
01 RAT
01 RAT LE
+ AVP RAT
FIGURE 4. Effect of subpressor dose of arginme-vasopressin (AVP; 2 ng/kg per min for 2 hours) on baroreflex function in Dl rats. The average
calculated baroreflex function lines before (open circle and solid line) and during (closed circle and dotted line) AVP infusions are shown in left
figure. All the baroreflex function slopes (baroreflex sensitivity) before (open circle) and during (closed circle) AVP infusion are shown in right
figure. Symbol and vertical line in right figure shows the mean ± I so of the slopes of baroreflex function lines obtained from LE rats. Otherwise,
the same as Figure 3.
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FIGURE 5. Effect of DDAVP on baroreflex function in Dl rats. The average calculated baroreflex function line before (open circle and solid line)
and during (closed circle and dotted line) DDAVP infusion are shown in left figure. All the baroreflex function slopes (baroreflex sensitivity) before
(open circle) and during (closed circle) DDAVP infusion are shown in right figure. Mean ±1 SDof slope before and during DDAVP infusion are
(7.0 ± 0.9) x Iff"* and (1Z0 ± 1.7) x 2(T\ respectively (P < 0.01). Otherwise, the same as Figure 3.
shown in Figure 5 (right). DDAVP increased the
slope in seven of eight Dl rats. In the remaining one,
the baroreflex function slope decreased during
DDAVP infusion. As a whole, the baroreflex func-
tion slope during DDAVP infusion [(12.0 ± 1.7) X
1CT4] was significantly steeper than that before treat-
ment [(7.0 ± 0.9) X 10"4, P < 0.01]. However, the
baroreflex function slope during DDAVP infusion
was not as steep as that during AVP infusion [(17.0
± 0.8) X 10- \ F,
 16 = 5.62, P < 0.05] or that found
4
 Pin LE rats [(19.0 ± 1.4) X
0.05].
10~ ]
 4 3 = 6.72,  <
Experiment 4. Effect of Acute Volume Expansion
on Baroreflex Function in Dl Rats
After 2 hours of volume expansion, body weight
had increased 12.2 ± 5.0 g (P < 0.05) and hematocrit
had decreased by 1.2 ± 0.2% (P < 0.01). However,
volume expansion did not change the mean arterial
pressure or pulse period.
Figure 6 (left) shows the average calculated baro-
reflex function lines before and during volume ex-
pansion. The individual baroreflex function slopes
obtained from each experiment are shown in Figure
200-
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FIGURE 6. Effect of acute volume expansion on baroreflex function in Dl rats. The average calculated baroreflex function lines before (open circle
and solid line) and during (closed circle and dotted line) volume expansion by 5% dextrose solution are shown in left figure All the baroreflex
function slopes (baroreflex sensitivity) before (open circle) and during (closed circle) volume expansion are shown in right figure. Otherwise, the
same as Figure 3.
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6 (right). The baroreflex function slope during vol-
ume expansion [(7.7 ± 1.1) X 1O~*] was not signif-
icantly different from that before volume expansion
[(8.2 ± 1.7) x 10"4].
Experiment 5. Effect of Vasopressin-Specific
Vascular Receptor Antagonist on Baroreflex
Function in LE Rats
The vasopressin-specific vascular receptor antag-
onist, d(CH2)5 Tyr(Me)AVP, increased mean arterial
pressure from 93 ± 2 to l01 ± 3 mm Hg in the first
10 minutes (P < 0.01) of infusion, but by 2 hours
the blood pressure and pulse period were not sig-
nificantly different from the control values. The
pressor effect of AVP at a dose of 100 ng/kg was
almost completely inhibited by d(CH2)5Tyr(Me)
AVP (49.7 ± 3.4 to 4.0 ± 1.2 mm Hg, P < 0.001).
As shown in Figure 7 (right and left), the baroreflex
function slope before treatment [(16.0 ± 2.3) X 10~4]
was not significantly different from that during in-
fusion of d(CH2)5Tyr(Me)AVP [(19.0 ± 1.7) X
10"*].
Experiment 6. Effect of Vasopressin-Specific
Vascular Receptor Antagonist on Baroreflex
Function in DI Rats Treated with AVP
The baroreflex sensitivity during AVP infusion
[(17.0 ± 0.9) X 10~4] was significantly higher than
that in control [(9.2 ± 0.9) X 10~4]. The baroreflex
sensitivity during combined treatment with AVP
and vasopressin-specific vascular receptor antago-
nist [(17.0 ± 1.1) X 10"4] was almost identical with
that during AVP infusion alone [(17.0 ± 0.9) x 10"4]
Experiment 7. Effect of Atropine on Baroreflex
Function in LE and DI Rats
Atropine significantly shortened the resting pulse
period both in LE (163 ± 8 to 125 ± 4 msec, P <
0.01) and DI (166 ± 6 to 129 ± 3 msec, P < 0.001)
rats, but did not affect mean arterial pressure. In
addition, atropine nearly abolished the baroreflex
function slope in both LE [(18.0 ± 2.1) X 10~4 to
(1.0 ± 0.3) X 10~\ P < 0.001] and DI rats [(6.3 ±
1.3) X 10~4 to (0.8 ± 0.3) X 1(T\ P < 0.001].
Discussion
The present study clearly demonstrates that, in
Brattleboro rats with hereditary hypothalamic dia-
betes insipidus and completely lacking endogenous
vasopressin, baroreflex sensitivity is greatly sup-
pressed compared with that in normal Long-Evans
rats. Intravenous administration of AVP at a sub-
pressor rate that achieved plasma AVP levels within
the physiological range, resulted in bradycardia and
restored baroreflex sensitivity toward normal in DI
rats. This suggests that vasopressin is a physiological
modulator of baroreflex function. The present re-
sults demonstrate that endogenous vasopressin
makes an important contribution to the maintenance
of baroreflex sensitivity in normal rats.
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It is widely recognized that systemic administra-
tion of vasopressin causes considerable bradycardia
in various species of animal. In the present study,
intravenous administration of very low amounts of
vasopressin into DI rats caused significant bradycar-
dia without change in mean arterial pressure. Since
a direct chronotropic effect of vasopressin is ob-
served only when pharmacological closes of vaso-
pressin are administered (Nakashima et al., 1982),
the chronotropic effect of vasopressin in low con-
centration is most likely due to an indirect action
mediated by the autonomic nervous system and/or
baroreceptor reflexes (Nakano, 1974). Mohring et al.
(1981) recently reported that heart rate fell more for
a given increase in arterial pressure during infusions
of vasopressin than during infusions of phenyleph-
rine or norepinephrine. Several authors also re-
ported that pressor responses to vasopressin were
augmented more than those to other vasopressor
substances after baroreceptor denervation or auto-
nomic blockade (Cowley et al., 1974; Matsuguchi
and Schmid, 1982). These results strongly suggest
that vasopressin, unlike most other vasopressor sub-
stances, augments baroreflex buffering action.
The mechanism by which vasopressin modulates
baroreflex function is not known, but may involve
a central action of the peptide. Liard et al. (1981)
reported that vasopressin administered selectively
into the vertebral artery of dogs induced a lesser
increase in mean arterial pressure and a greater
decrease in heart rate than the same infusion given
intravenously, despite similar increases in plasma
vasopressin concentration. They postulated that cir-
culating vasopressin has an effect on a structure in
the central nervous system involved in cardiovas-
cular control, possibly by affecting the baroreceptor
reflex. However, the centrally mediated cardiovas-
cular actions of vasopressin appear to be complex.
The diversity of the results observed may, in part,
be due to species difference and the route of admin-
istration. Varma et al. (1969) administered vasopres-
sin into the ventricular system of the brain of anes-
thetized dogs and observed a pronounced slowing
of heart rate. This response was inhibited by vagot-
omy, indicating the involvement of parasympathetic
neural pathways. In contrast, Matsuguchi et al.
(1982) reported that microinjection of vasopressin
into the nucleus tractus solitarius caused tachycardia
in anesthetized rats. We have observed that intra-
cerebroventricular infusion of vasopressin at a rate
of 2 ng/kg per min causes transient tachycardia in
conscious DI rats (Imai et al., 1983), whereas the
same dose of vasopressin infused intravenously
caused bradycardia. Such results indicate that car-
diovascular effects of centrally administered vaso-
pressin are different from those observed after intra-
venous injection, at least in the rat. It is not yet clear
whether circulating vasopressin can cross the blood
brain barrier, and since vasopressin may act at sev-
eral loci within baroreflex pathways, it is difficult to
postulate which part (central or peripheral) of the
baroreflex pathways may be affected by intravenous
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infusions of vasopressin in DI rats. Some effects of
circulating vasoactive substances like angiotensin II
and prostaglandins are mediated via the central
nervous system (Scroop and Lowe, 1969, Ferrario et
al., 1970; Lavery et al., 1970; Sweet et al., 1971).
Izdebska et al. (1981) reported that intracerebrov-
entricular injection of lysine-vasopressin into anes-
thetized rats enhanced reflex bradycardia induced
by a blood pressure rise. We also observed enhanced
baroreflex sensitivity by central infusion of vaso-
pressin in conscious DI rats (Imai et al., 1983). Such
an effect is mimicked by vasopressin administered
intravenously, as shown in the present study, sug-
gesting vasopressin administered intravenously may
act on the central nervous system.
There is now anatomical evidence linking hypo-
thalamic vasopressin neurones to cardiovascular
mid-brain center. Extra-hypothalamic-pituitary va-
sopressinergic neuronal projections to some of the
central cardiovascular regulatory centers have been
described. The paraventricular nucleus and su-
praoptic nucleus, main vasopressin synthetizing nu-
clei, have been shown to send projections to the
locus coeruleus, nucleus tractus solitarius, and an-
teroventral third ventricular (AV3V) region (Saper
et al., 1976; Buijs et al., 1978; Sofroniew, 1980), as
well as to receive noradrenergic synapses from these
areas (Sawchenko and Swanson, 1981). Vasopressin
usually increases the sensitivity of the baroreceptor
reflex through its central action in rats. (Izdebska et
al., 1982; Imai et al., 1983). Berecek et al. (1982)
reported that stimulation of the paraventricular nu-
cleus produced a frequency-dependent bradycardia
in rats. However, it has also been reported that
stimulation of vasopressin synthetizing nuclei atten-
tuates the bradycardia produced by carotid sinus
stimulation, whereas ablation of these areas in-
creases reflex bradycardia in cats (Ciriello and Ca-
laresu, 1980). Intiacisternal administration of vaso-
pressin also attentuated the blood-pressure-lower-
ing effect of carotid sinus stimulation in dogs, sug-
gesting suppressed inhibition of central sympathetic
vasomotor activity (Brattstrom and Kalkoff, 1970).
Thus, the central action of vasopressin on baroreflex
function and central cardiovascular control mecha-
nisms may depend on the species of animal or on
its precise anatomical site of action.
The peripheral as well as the central pathways of
the baroreceptor reflex could be affected by vaso-
pressin. It has been reported that local application
of a variety of drugs to the carotid sinus, or stimu-
lation of sympathetic fibers innervating the sinus
wall, results in a fall in blood pressure through
stimulation of the afferent limb of the reflex (Kir-
cheim, 1976). Although the effect of vasopressin on
the baroreflex afferent pathway has not yet been
studied, the possibility remains that vasopressin may
also modulate the baroreflex function via this route.
In the present study, not only AVP but also
DDAVP, a vasopressin analogue with potent anti-
diuretic activity but with minimal vasoconstrictor
action, caused bradycardia and increased baroreflex
sensitivity in DI rats. On the other hand, a specific
vascular receptor antagonist of vasopressin did not
affect the baroreflex sensitivity or heart rate in nor-
mal LE rats. The present results suggest that the
effect of vasopressin on the baroreflex are mediated
through a vasopressin receptor more similar to the
vasopressin renal receptor than the vascular recep-
tor. The type of vasopressin receptor mediating the
central actions of vasopressin is not yet known.
Recently, LeMoal et al. (1981) reported that dPTyr
(Me) AVP, one of the specific vascular receptor
antagonists of vasopressin, abolished the effect of
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vasopressin on active avoidance behavior. However,
Weingartner et al. (1981) reported that DDAVP al-
tered aspects of memory function in adult humans.
This information suggests that the central effects of
vasopressin may be mediated through both types of
vasopressin receptor, or a third type of receptor
partially influenced by vasopressin and DDAVP.
The restoration of baroreflex sensitivity by DDAVP
in DI rats may be explained in part, by dual central
vasopressin receptors. However, the possibility re-
mains that the central action of vasopressin is me-
diated through a receptor different from both the
renal and vascular receptors of vasopressin. It has
recently been shown that some of the activities of
vasopressin in the central nervous system can be
performed by a smaller fragment of the molecule
than is needed or used for peripheral functions
(Hoffman et al., 1977; Stewart, 1982).
In the present study, the same dose of AVP and
DDAVP increased baroreflex sensitivity and caused
bradycardia in DI rats. Although the change in body
weight by DDAVP was not detectable, it is known
that the antidiuretic potency of DDAVP is 3 times
higher than AVP. To exclude the possibility that
these effects were due to fluid retention, DI rats
were volume expanded with 5% dextrose solution.
This, however, did not change the heart rate or
baroreflex sensitivity.
The rate of change of the arterial pressure is
considered to be an important influence on the
baroreflex heart rate response (Kirchheim, 1976).
However, there was no difference between LE and
DI rats in the pressor effect or the time to attain
peak mean arterial pressure following phenyleph-
rine. Thus, it can be concluded that the difference
in baroreflex sensitivity between LE and DI rats was
not due to differences in the dynamic characteristics
of the pressure stimulus.
The heart rate change in response to transient
increases in arterial pressure is dependent mainly
on the vagus nerve (Warner and Cox, 1962; Scher
and Young, 1970; Thames and Kontos, 1970; Pick-
ering et al., 1972). The present study also showed
that reflex slowing of the heart in response to tran-
sient increases in arterial pressure disappeared al-
most completely after atropine in both LE and DI
rats. If the difference of baroreflex sensitivity be-
tween LE and DI rats was partly due to differences
in cardiac sympathetic activity, the baroreflex func-
tion slope in LE rats should be steeper than that in
DI rats when parasympathetic tone was abolished.
After atropine treatment, however, the baroreflex
function slopes were abolished in both LE and DI
rats. Thus, it would appear that the difference in
baroreflex sensitivity between LE and DI rats is
attributable mainly to differences in the parasym-
pathetic response to a transient increase in blood
pressure.
From the results of present experiments, it is ob-
vious that endogenous and exogenous vasopressin
can modulate the sensitivity of the baroreflex. Since
Circulation Research/Vol. 53, No. 2, August 1983
AVP and DDAVP decreased heart rate without sig-
nificant change in arterial pressure, vasopressin may
modulate not only the sensitivity but also the set
point of the baroreflex (Korner, 1971).
The results obtained in DI rats and the change in
baroreflex sensitivity brought about by infusion of
vasopressin provide strong evidence that vasopres-
sin may be an important physiological modulator of
baroreflex function.
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